 |
|
MU scientists 'see' how HIV matures into an infection
October 02, 2008Researchers have speculated about the process, but never known until now
COLUMBIA, Mo. - After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature.
"We actually saw the process occur," said Chun Tang, assistant professor of biochemistry in the MU School of Medicine. "This is something that has never been done before. We now understand more about the maturation process. We hope this will be a stepping stone to intervening before the infection progresses."
The HIV-1 protease is responsible for releasing the essential building blocks of an infective HIV-1 viral particle, the culprit of AIDS. The HIV-1 protease is one of the primary targets of therapeutic treatment. However, the viral enzyme is constantly mutating in an effort to gain drug resistance.
"HIV-1 protease is not an active enzyme when it is first expressed in cells. It has to be activated to do its job," Tang said. "What we were able to see is how it self-activates from an immature form when the virus is not infective into a mature form when the virus gains infectivity."
Tang and his colleagues used a novel NMR method called paramagnetic resonance relaxation enhancement and were able to see the temporary joining of two halves of HIV-1 protease precursor, something that had not been accessible before using conventional techniques.
The researchers discovered that the 'tail,' or the flanking amino acid residues, of the HIV-1 protease precursor go through a temporarily formed tunnel where the tail is cut off. At this point, the protease becomes active, the maturation process proceeds, and the virus becomes infective.
"The more we understand about the virus, especially about the maturation into infection, the more we can do to identify novel therapeutics," Tang said.
University of Missouri-Columbia
The HIV-1 protease is responsible for releasing the essential building blocks of an infective HIV-1 viral particle, the culprit of AIDS. The HIV-1 protease is one of the primary targets of therapeutic treatment. However, the viral enzyme is constantly mutating in an effort to gain drug resistance.
"HIV-1 protease is not an active enzyme when it is first expressed in cells. It has to be activated to do its job," Tang said. "What we were able to see is how it self-activates from an immature form when the virus is not infective into a mature form when the virus gains infectivity."
Tang and his colleagues used a novel NMR method called paramagnetic resonance relaxation enhancement and were able to see the temporary joining of two halves of HIV-1 protease precursor, something that had not been accessible before using conventional techniques.
The researchers discovered that the 'tail,' or the flanking amino acid residues, of the HIV-1 protease precursor go through a temporarily formed tunnel where the tail is cut off. At this point, the protease becomes active, the maturation process proceeds, and the virus becomes infective.
"The more we understand about the virus, especially about the maturation into infection, the more we can do to identify novel therapeutics," Tang said.
University of Missouri-Columbia
Compound has potential for new class of AIDS drugs
Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs.
Organic & Biomolecular Chemistry
First Advance Articles Now Available Free Online The first issue of Organic & Biomolecular Chemistry, formed from the merger and strategic development of Perkin Transactions 1 & 2, will be published on 10 January 2003. The electronic version will go up on 23 December 2002. Barbara Imperiali, Francois Diederich, Ben Feringa and Chi-Huey Wong are amongst the first eminent scientists to publish Advance Articles in the journal. Further details are given below. The first issue will also feature contributions from Steve Ley, Jay Siegel and Michael Burkart, these will be available online soon. Advance Articles Now Available on the Journal Website Include:- PERSPECTIVE - &nbs
Specific Genotype Could Increase Resistance To HIV Drug Therapy (p 383)
A specific mutation of a gene which influences the expression of a glycoprotein transporter protein involved in the body's resistance to drugs and other toxins is detailed in a research letter in this week's issue of THE LANCET. Results of the study suggest that drug therapies used in treating HIV-1 infection (notably protease inhibitors ) may not be as effective in West African and African American ethnic groups compared with Caucasian populations. The variability of P-glycoprotein expression between individuals is linked to a C3435T alteration of the human MDR1 gene. Concentration of P-glycoprotein in intestinal epithelial cells and in some lymphoid cells is substantially lower in people w
LIPODYSTROPHY RISK FROM HIV-1 THERAPY (p 592)
The risk of lipodystrophy (abnormal fat distribution) in HIV-1 individuals undergoing antiretroviral therapy cannot be attributed to one antiretroviral agent, conclude authors of a study in this week's issue of THE LANCET. Lipodystrophy among HIV-1-infected patients receiving antiretroviral therapy was formally described as a clinical entity in 1998. However, the risk factors for lipodystrophy in patients infected with HIV-1 who are treated with highly active antiretroviral therapy (HAART) containing HIV-1 protease inhibitors are poorly understood. Esteban Martinez and colleagues from the University of Barcelona, Spain, aimed to identify the risk factors for lipodystrophy in HIV-1-infected a
More Hiv-1 Protease Current Events and Hiv-1 Protease News Articles
| © 2009 BrightSurf.com |